Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer

Wang, Jian; Sahengbieke, Sana; Xu, Xiaoping; Zhang, Lei; Xu, Xiaoming; Sun, Long; Deng, Qun; Wang, Da; Chen, Dong; Pan, Yuan; Liu, Zhaohui; Yu, Shaojun

doi:10.2147/ott.s167780

Cited by 6 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Yang et al [32] suggested that high expression of STC2 promotes the migration and invasion of head and neck squamous cell carcinoma cells in vitro and in vivo through the PI3K/AKT pathway may. Wang et al [33] speculated that STC2 promoted lymphatic metastasis through VEGF-C/VEGF-D/VEGFR-3 pathway and EMT-related molecules in colorectal cancer. One study elaborated that STC2 contributes to hepatocellular carcinoma progression and metastasis by affecting cells viability, colony formation, and migration ability in a dominant-positive manner.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of high stanniocalcin 2 expression in solid cancers

Zha

Kong

et al. 2019

Medicine

View full text Add to dashboard Cite

Background:Several studies have explored the prognostic value of stanniocalcin 2 (STC2) in various cancers, but obtained inconsistent results. Therefore, this meta-analysis was performed to determine the prognostic and clinicopathologic significance of STC2 in various cancers.Methods:Eligible studies were identified by searching the online databases PubMed, Embase, Web of Science, and the China National Knowledge Infrastructure up to March 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) and were calculated to clarify the correlation between STC2 expression and prognosis of different cancers. Odds ratios (ORs) with 95% CI were selected to appraise the correlation between STC2 with clinicopathologic characteristics of patients with cancer.Results:A total of 16 eligible studies with 4074 patients with cancer were included in our meta-analysis. The results showed that high STC2 expression can predict poor overall survival (OS) for cancer (HR = 1.48, 95% CI: 1.15–1.90, P = .002). Subgroup analysis found that high STC2 expression was associated with worse OS in Asian (HR = 1.85, 95% CI: 1.35–2.55), the reported directly from articles group (HR = 1.39, 95% CI: 1.05–1.84), survival curves group (HR = 1.93, 95% CI: 1.36–2.74), and gastric cancer (HR = 1.43, 95% CI: 1.04–1.95). Furthermore, high STC2 expression was significantly related to advanced T stage (OR = 1.83, 95% CI: 1.17–2.86, P = .008), lymph node metastasis (OR = 2.29, 95% CI: 1.51–3.45, P < .001), lymphatic invasion (OR = 2.15, 95% CI: 1.53–3.02, P < .001), venous invasion (OR = 1.97, 95% CI: 1.30–2.99, P = .001), and more advanced clinical stage (OR = 2.36, 95% CI: 1.74–3.19, P < .001)Conclusion:Elevated expression of STC2 suggested a poor prognosis in patients with cancer and may serve as a new tumor marker to monitor cancer development and progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of high stanniocalcin 2 expression in solid cancers

Zha

Kong

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…45 Further investigations have shown that STC2 promotes epithelial-mesenchymal transition (EMT), migration, and chemoresistance in CRC, involving activation of the ERK/MEK and PI3K/ AKT signaling pathways. 45,46 In addition, STC2 has been associated with anti-VEGF resistance and chemoresistance to oxaliplatin. 47,48 These findings highlight the clinical significance of STC2 in CRC and its involvement in EMT and chemoresistance through multiple potential pathways.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, elevated serum STC2 levels have been correlated with poor patient survival and pathological grade, suggesting the potential of STC2 as a serum biomarker 45 . Further investigations have shown that STC2 promotes epithelial–mesenchymal transition (EMT), migration, and chemoresistance in CRC, involving activation of the ERK/MEK and PI3K/AKT signaling pathways 45,46 . In addition, STC2 has been associated with anti‐VEGF resistance and chemoresistance to oxaliplatin 47,48 .…”

Section: Discussionmentioning

confidence: 99%

Integrative analysis of PTEN‐related hub genes and validating drug targets for colorectal cancer

Wang,

Zhu,

Wang

2024

Precision Medical Sciences

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a heterogeneous disease and one of the most prevalent malignancies worldwide. Previous research has indicated that phosphatase and tensin homolog (PTEN)‐related genes found in CRC may serve as potential biomarkers for individualized treatment options. The present study aimed to examine the association between PTEN‐related genes and the prognosis of CRC patients by evaluating the significance of PTEN‐related hub genes and determining potential mechanisms and genes associated with them. Gene expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. At present, PTEN mutations have been identified in 7% of CRC patients, according to the most recent TCGA data. Differential expression analysis revealed 54 genes as differentially expressed genes (DEGs) between PTEN‐related genes and GEO databases (GSE39582 and GSE6263). Further gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted on PTEN‐related DEGs. The prognostic efficacy of the PTEN‐related DEG signature was assessed using Kaplan–Meier survival and receiver operating characteristic curve analyses. Bioinformatics methods were utilized to analyze the correlation between PTEN‐related DEGs and CRC prognosis, survival, and drug efficacy. Through these analyses, eight prognostic‐related PTEN‐related hub genes (PPARGC1A, NTRK2, ANK2, PLCB4, STC2, PLAU, CDKN1A, and HPGDS) were identified and a risk prognosis model was constructed. Notably, NTRK2 and HPGDS were found to affect drug treatment response in CRC. Targeting these prognostic‐related PTEN‐related hub genes can regulate cell death signaling, which may benefit the prognosis of CRC patients and improve drug sensitivity.

show abstract

“…In colorectal cancer, CCDC85B (also known as DIPA) is a carcinogenetic gene (22). It could be found on the centrosome and directly interacts with p78 and influences malignant transformation by modulating gene transcription (23).…”

Section: Discussionmentioning

confidence: 99%

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Yang¹,

Zhang²,

Liu³

et al. 2023

Ann Transl Med

View full text Add to dashboard Cite

Background: The prognosis of esophageal squamous cell carcinoma (ESCC) is improved by neoadjuvant chemoradiotherapy (nCRT), especially for patients with pathologic complete response (pCR). Despite the efforts to predict treatment response using multimodality, no molecule has proven to be a strong biomarker.This study aimed to profile the expression of exosome transcriptome that could predict pCR in ESCC before and after nCRT.Methods: We collected paired blood samples of 15 patients with ESCC who received nCRT and radical surgery. They were divided into 3 groups: (A) residual tumor in the first clinical response evaluation (CRE-1), (B) no residual tumor in CRE-1 but with residual tumor in CRE-2 which was performed after 5-6 weeks, and (C) no residual tumor in CRE-1 or CRE-2. For each patient, the blood sample was collected before nCRT (time point 0); and then 6 weeks after nCRT, the clinical response was evaluated, and another blood sample was collected (time point 1).Results: Using the intersection of different sets, we found 23 progression-associated messenger RNAs (mRNAs) and 67 remission-associated mRNAs. Between remission-associated mRNAs and the targets of progression-associated (carcinogenic) microRNAs (miRNAs), the intersection was acquired, and 2 miRNA-mRNA networks (IFIT2-miR-3615-IFIT2-miR-484 and BTN3A3-miR-6803-3p) were identified. Among the intersection of progression-associated (carcinogenic) mRNAs and the targets of remission-associated miRNAs, there is a network with miR-132-3p (remission-associated miRNA) located at the core, matched with DICER1, KLHL8, ANKRD12, ASH1L, and IMP4.Conclusions: Our findings identified altered plasma exosome RNAs among the different groups and between different time points of nCRT, as well as the corresponding enrichments and regulatory networks, which may serve as potentially predictors of treatment response for patients with ESCC after nCRT.

show abstract

Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer

Cited by 6 publications

References 48 publications

Prognostic value of high stanniocalcin 2 expression in solid cancers

Prognostic value of high stanniocalcin 2 expression in solid cancers

Integrative analysis of PTEN‐related hub genes and validating drug targets for colorectal cancer

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Contact Info

Product

Resources

About